Combination of Rivaroxaban And Aspirin Improves CV Outcomes: COMPASS Trial - Video
|
Overview
Cardiovascular diseases are the leading cause of death globally. Though new medications and the use of effective secondary prevention strategies, 5% to 10% of patients with cardiovascular disease have recurrent events each year with worst outcomes mostly being cardiac death. Rivaroxaban is used to prevent blood clots from forming due to atrial fibrillation however its known to cause major risk of bleeding when given higher doses, hence its safety is a question mark for its regular use.
A new trial COMPASS by Dr. John W. Eikelboom, M.B.B.S. and team revealed that patients with stable atherosclerotic vascular disease, those assigned to rivaroxaban (2.5 mg twice daily) plus aspirin had better cardiovascular outcomes and more major bleeding events than those assigned to aspirin alone. 5 mg of rivaroxaban twice daily alone did not help any better than aspirin alone and resulted in more major bleeding events.
For more details, checkout the full story on link below:
Speakers
Dr. Nandita Mohan
BDS, MDS( Pedodontics and Preventive Dentistry)
Dr. Nandita Mohan is a practicing pediatric dentist with more than 5 years of clinical work experience. Along with this, she is equally interested in keeping herself up to date about the latest developments in the field of medicine and dentistry which is the driving force for her to be in association with Medical Dialogues. She also has her name attached with many publications; both national and international. She has pursued her BDS from Rajiv Gandhi University of Health Sciences, Bangalore and later went to enter her dream specialty (MDS) in the Department of Pedodontics and Preventive Dentistry from Pt. B.D. Sharma University of Health Sciences. Through all the years of experience, her core interest in learning something new has never stopped. She can be contacted at editorial@medicaldialogues.in. Contact no. 011-43720751